Results 31 to 40 of about 7,329,727 (241)

Airway mucus and ¹²⁹Xe MRI ventilation after single inhaler triple therapy in asthma. [PDF]

ERJ Open Res
Background In asthma, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was previously demonstrated to improve forced expiratory volume in 1 s (FEV1) and asthma control, but the mechanism by which this occurs, especially at the level of the small airways, is not well-understood. We asked the question, does FF/
Mozaffaripour A, Tcherner S, Durom E, Kooner HK, McIntosh MJ, Sherwood M, Paul N, Serajeddini H, Bhalla A, Yamashita C, Parraga G.   +10 more
europepmc   +4 more sources

Switching from multiple-inhaler triple therapy to single, extra fine-inhaler triple therapy in severe refractory asthma with EGPA: beyond control. Case report and review of the literature

Drugs in Context
Eosinophilic granulomatosis with polyangiitis is a rare systemic vasculitis associated with asthma, eosinophilia and multi-organ involvement. This case report describes a 69-year-old male with severe, poorly controlled asthma who was diagnosed with ...
Francesco Menzella, Marcello Cottini, Silvia Tonin, Lorenzo Corsi, Annamaria Bosi, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Matteo Tacconi, Carlo Lombardi   +9 more
doaj   +2 more sources

When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.

International journal of chronic obstructive pulmonary disease, 2019
While single-inhaler triple therapy (SITT) devices were not available when the Global Initiative for Chronic Obstructive Lung Disease strategy and National Institute for Health and Care Excellence guidelines were developed, two devices are now available in the UK.
Gaduzo, S., McGovern, V., Roberts, J., Scullion, J. E., Singh, D.   +4 more
openaire   +6 more sources

Single-versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes

Frontiers in Pharmacology
This retrospective study aimed to compare the clinical and economic outcomes of single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) in a large cohort of COPD patients.
M. Asunción González-González, M. Aránzazu Pedrosa-Naudín, Diego Fernández-Lázaro, Isabel Díaz Planelles, F. Javier Álvarez, F. Javier Álvarez, F. Javier Álvarez, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón   +11 more
doaj   +3 more sources

Real-World Effectiveness of Single-Inhaler Triple Treatment Through Assorted Respiratory Outcomes When Switched From Multiple-Inhaler Triple Therapies (RESTART): A Prospective Cohort Study of Korean Patients With COPD [PDF]

International Journal of COPD
Hana Lim,1,* Dong Han Kim,2,* Song Hee Hong,2 Juyoung Shin,1 Hyesung Lee,3 Kyeongcheol Shin,4 Seung Won Ra,5,6 Seung Jun Lee7,8 1Department of Bio Health Regulatory Science, Sungkyunkwan University, Suwon, Korea; 2Department of Social Pharmacy ...
Lim H, Kim DH, Hong SH, Shin J, Lee H, Shin K, Ra SW, Lee SJ   +7 more
doaj   +1 more source

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Pulmonary Therapy
Introduction Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β2-agonist; however, characterization of elderly
Russell A. Settipane, Guillaume Germain, Francois Laliberté, Malena Mahendran, Annalise Hilts, Mei Sheng Duh, Rosirene Paczkowski, Emmeline Burrows   +7 more
doaj   +2 more sources

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Robyn Kendall,1 Alan A Martin,2 Dhvani Shah,3 Soham Shukla,4 Chris Compton,5 Afisi S Ismaila4,6 1ICON Health Economics, ICON plc, Vancouver, BC, Canada; 2Value Evidence and Outcomes, GSK, London, UK; 3ICON Health Economics, ICON plc, New York, NY, USA ...
Kendall R, Martin AA, Shah D, Shukla S, Compton C, Ismaila AS.   +5 more
europepmc   +2 more sources

Real-World Effectiveness of Single-Inhaler Triple Therapy for COPD: Impact of Diabetes Comorbidity

COPD
Background Type 2 diabetes is a frequent comorbidity in chronic obstructive pulmonary disease (COPD) patients, with the GOLD treatment recommendations asserting that the presence of diabetes be disregarded in the choice of treatment.Methods In a cohort ...
Sophia Eilat-Tsanani, Pierre Ernst, Samy Suissa   +2 more
doaj   +3 more sources

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Ruan Z, Wang C, Yuan S, Fan Y, Xu B, Cong X, Li D, Miao Q.   +7 more
europepmc   +2 more sources

Single-Inhaler Triple versus Dual Therapy in Patients with COPD [PDF]

New England Journal of Medicine, 2018
In the randomized Informing the Pathway of COPD Treatment (IMPACT) trial involving more than 10,000 patients with chronic obstructive pulmonary disease (COPD), Lipson and colleagues (May 3 issue) compared a once- daily combination of f luticasone furoate (an inhaled glucocorticoid), umeclidinium (a long- acting muscarinic antagonist [LAMA]), and ...
Wedzicha, JA, Banerji, D, Kostikas, K
openaire   +7 more sources